| 驱动基因阴性的肺腺癌软脑膜转移预后分析 |
| 投稿时间：2024-10-20 修订日期：2024-12-19 点此下载全文 |
| 引用本文：雒静,陶洁,张琰.驱动基因阴性的肺腺癌软脑膜转移预后分析[J].医学研究杂志,2025,54(5):105-109, 123 |
| DOI：
10.11969/j.issn.1673-548X.2025.05.020 |
| 摘要点击次数: 3 |
| 全文下载次数: 3 |
|
| 基金项目:天山英才-医药卫生高层次人才项目(TSYC202301B098) |
|
| 中文摘要:目的 探讨影响驱动基因阴性的肺腺癌软脑膜转移(leptomeningeal metastases,LM)患者预后的因素。方法 回顾性收集2011年1月1日~2023年12月31日就诊于新疆医科大学附属肿瘤医院驱动基因阴性的肺腺癌并发软脑膜转移患者的临床资料,随访其生存期。结果 58例肺腺癌软脑膜转移患者生存时间为0~38.0 个月,中位总生存期(median overall survival,mOS)为5.0个月,1年生存率为25.9%,33例患者接受了抗肿瘤治疗,接受抗肿瘤治疗患者的生存期明显长于未接受抗肿瘤治疗的患者(8.0个月vs 2.0个月,P=0.006),其中12例患者接受了化疗联合全脑放疗,接受化疗联合放疗的患者和未接受化疗联合放疗的患者的mOS分别为6.0和3.0个月(P=0.098)。21例患者仅接受了全身化疗,接受单一化疗和接受化疗联合放疗的患者的mOS分别为6.0和8.0个月(P=0.497)。诊断LM时年龄＜60岁的患者生存期延长(8.0个月 vs 2.0个月,P=0.011)。患者是否接受抗肿瘤治疗是肺腺癌 LM患者的独立预后因素(HR=0.489,95% CI:0.281~0.849,P=0.011)。结论诊断LM时年龄＜60岁、接受抗肿瘤治疗可延长驱动基因阴性的肺腺癌软脑膜转移患者的预后,其中接受抗肿瘤治疗是影响患者预后的独立影响因子。 |
| 中文关键词:肺腺癌 软脑膜转移 预后 |
| |
| Prognostic Analysis of Leptomeningeal Metastasis in Lung Adenocarcinoma with Negative Driver Gene |
|
|
| Abstract:Objective To investigate the prognostic factors of leptomeningeal metastasis of lung adenocarcinoma without driving gene. Methods Retrospectively collected the clinical data of lung adenocarcinoma patients with leptomeningeal metastasis without driving gene in the affiliated Cancer Hospital of Xinjiang Medical University from January 1,2011 to December 31,2023, and followed up their survival time. Results Among the 58 patients with leptomeningeal metastasis of lung adenocarcinoma, the survival time was 0-38.0months, the median overall survival time (mOS) was 5.0months, and the one-year survival rate was 25.9%. 33 patients received antineoplastic therapy, and the survival time of patients receiving antineoplastic therapy was significantly longer than that of patients without antineoplastic therapy (8.0months vs 2.0months, P=0.006). Among them, 12 patients received chemotherapy combined with whole brain radiotherapy. The mOS of patients who received chemotherapy combined with radiotherapy and those who did not receive chemotherapy combined with radiotherapy were 6.0 and 3.0months(P=0.098). 21 patients received only systemic chemotherapy, and the mOS of patients receiving chemotherapy alone and chemotherapy combined with radiotherapy were 6.0 and 8.0months(P=0.497). The survival time of patients less than 60 years old at the time of diagnosis of LM was prolonged (8.0months vs 2.0months,P= 0.011). Whether patients received antineoplastic therapy or not was an independent prognostic factor for patients with lung adenocarcinoma LM (HR=0.489,95% CI:0.281-0.849).Conclusion Age < 60 years old and antineoplastic therapy can prolong the prognosis of patients with leptomeningeal metastasis of lung adenocarcinoma with negative driver gene, and antineoplastic therapy is an independent factor affecting the prognosis of patients. |
| keywords:Lung adenocarcinoma Meningeal metastasis Prognosis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
